R

ise and shine, everyone, another busy day is on the way. Most every day is busy, though, is it not? Well, no matter. Busy is good, as they say. After all, consider the alternatives. While you ponder, please join us for our ritual cup of stimulation, which is a much-needed boost this morning, thanks to a growing to-do list of meetings and phone calls and deadlines – oh my! Meanwhile, we have gathered a few items of interest to help you along. Hopefully, this will be equally stimulating. Hope you conquer the world and stay in touch …

The Food and Drug Administration placed a partial hold on five Celgene (CELG) clinical trials and a full hold on another involving a PD-L1 immunotherapy after seeing risks in similar studies involving Merck’s Keytruda, MarketWatch reports. On Wednesday, the agency placed a partial hold on three clinical trials testing Bristol-Myers Squibb’s (BMY) Opdivo immunotherapy in combination with other medicines for multiple myeloma, Pharmaphorum notes.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of news in health and medicine.